Nonalcoholic Fatty Liver
51
6
11
26
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.9%
2 terminated out of 51 trials
92.9%
+6.3% vs benchmark
12%
6 trials in Phase 3/4
35%
9 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 26 completed trials
Clinical Trials (51)
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Effect of a GnRH Analog on Hepatic Steatosis
High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver
Assessment of Fatty Liver With Thermo-acoustic Device
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Identification of Liver Fibrosis Biomarkers
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Weight, Energy, Lipids, and the Liver (WELL) Study
Digital Therapy for Fatty Liver Disease
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Accurate Point of Care Liver Disease Diagnostics
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
The Liver Health Study for Patients with NAFLD